PTGX
Protagonist Therapeutics, Inc. NASDAQ Listed Aug 11, 2016$98.87
Mkt Cap $6.4B
52w Low $41.60
86.5% of range
52w High $107.84
50d MA $99.30
200d MA $80.44
P/E (TTM)
-48.0x
EV/EBITDA
-42.4x
P/B
10.2x
Debt/Equity
0.0x
ROE
-21.2%
P/FCF
99.0x
RSI (14)
—
ATR (14)
—
Beta
2.11
50d MA
$99.30
200d MA
$80.44
Avg Volume
773.8K
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
7707 Gateway Boulevard · Newark, CA 94560-1160 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.65 | 0.06 | +109.2% | 103.97 | -0.4% | -4.9% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -0.53 | -0.69 | -30.2% | 87.10 | +0.5% | +1.5% | +5.7% | +8.2% | +4.8% | +8.9% | — |
| Nov 6, 2025 | AMC | -0.59 | -0.62 | -5.1% | 79.78 | +0.4% | -0.3% | +4.3% | +7.2% | +6.4% | +4.3% | — |
| Aug 6, 2025 | AMC | -0.53 | -0.55 | -3.8% | 53.87 | +0.5% | -5.4% | -5.2% | -0.2% | +1.2% | +5.3% | — |
| May 6, 2025 | AMC | -0.50 | -0.19 | +62.0% | 42.01 | -0.6% | +2.6% | +4.5% | +2.3% | +7.8% | +5.4% | — |
| Feb 21, 2025 | AMC | 0.06 | 1.98 | +3200.0% | 38.75 | +0.0% | -7.1% | -9.4% | -6.7% | -6.2% | -3.0% | — |
| Nov 7, 2024 | AMC | -0.59 | -0.54 | +8.5% | 47.61 | +2.6% | -2.9% | -2.3% | -9.3% | -10.4% | -13.8% | — |
| Aug 6, 2024 | AMC | -0.50 | -0.50 | +0.0% | 36.21 | +1.2% | -1.2% | +2.7% | +6.9% | +12.1% | +11.3% | — |
| May 7, 2024 | AMC | 1.19 | 3.26 | +173.9% | 25.79 | +5.0% | +5.1% | +9.6% | +9.5% | +13.7% | +14.8% | — |
| Feb 27, 2024 | AMC | 0.03 | 0.44 | +1425.3% | 29.59 | +1.4% | +2.8% | +2.7% | +8.7% | +7.0% | +4.6% | — |
| Nov 2, 2023 | AMC | -0.68 | -0.58 | +14.7% | 15.41 | +2.3% | +8.0% | +5.7% | +6.9% | +3.6% | -2.4% | — |
| Aug 3, 2023 | AMC | -0.65 | -0.68 | -4.6% | 18.57 | -0.2% | +3.3% | +1.9% | -2.0% | -1.8% | +1.2% | — |
| May 4, 2023 | AMC | -0.69 | -0.67 | +2.9% | 23.60 | +4.8% | +5.1% | +5.6% | +7.0% | +6.0% | +4.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Truist | Maintains | Buy → Buy | — | $104.72 | $105.96 | +1.2% | +0.7% | -0.9% | +1.2% | +0.7% | +1.1% |
| Apr 7 | Clear Street | Maintains | Buy → Buy | — | $102.89 | $103.43 | +0.5% | +0.8% | -0.8% | +1.2% | -4.0% | -5.2% |
| Mar 19 | Barclays | Maintains | Overweight → Overweight | — | $97.09 | $98.45 | +1.4% | +4.7% | +1.8% | +1.5% | +3.4% | +7.4% |
| Mar 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $97.09 | $98.45 | +1.4% | +4.7% | +1.8% | +1.5% | +3.4% | +7.4% |
| Mar 19 | JP Morgan | Maintains | Overweight → Overweight | — | $97.09 | $98.45 | +1.4% | +4.7% | +1.8% | +1.5% | +3.4% | +7.4% |
| Mar 19 | Citigroup | Maintains | Buy → Buy | — | $97.09 | $98.45 | +1.4% | +4.7% | +1.8% | +1.5% | +3.4% | +7.4% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $94.24 | $92.56 | -1.8% | -3.1% | +0.6% | -3.0% | -2.3% | +2.6% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $87.10 | $87.50 | +0.5% | +1.5% | +5.7% | +8.2% | +4.8% | +8.9% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $87.10 | $87.50 | +0.5% | +1.5% | +5.7% | +8.2% | +4.8% | +8.9% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $87.10 | $87.50 | +0.5% | +1.5% | +5.7% | +8.2% | +4.8% | +8.9% |
| Feb 2 | Jefferies | Maintains | Buy → Buy | — | $81.80 | $81.80 | +0.0% | +1.5% | +4.6% | +1.8% | -1.4% | +3.3% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $79.73 | $79.77 | +0.1% | +2.6% | +4.2% | +7.3% | +4.5% | +1.2% |
| Jan 5 | Truist | Maintains | Buy → Buy | — | $87.18 | $87.53 | +0.4% | -3.4% | -5.6% | -5.6% | -8.0% | -8.0% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $91.54 | $91.41 | -0.1% | -2.4% | -6.3% | -6.0% | -4.5% | -3.1% |
| Dec 8 | Citigroup | Maintains | Buy → Buy | — | $89.65 | $90.94 | +1.4% | +0.7% | -1.2% | +1.9% | +2.9% | +6.4% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $79.54 | $80.58 | +1.3% | +4.6% | +7.6% | +6.7% | +4.7% | +6.4% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.3% | +7.2% | +6.4% | +4.3% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.3% | +7.2% | +6.4% | +4.3% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.3% | +7.2% | +6.4% | +4.3% |
| Oct 28 | Wedbush | Maintains | Outperform → Outperform | — | $75.25 | $75.06 | -0.3% | +4.3% | +1.9% | +3.5% | +4.5% | +0.9% |
| Oct 28 | Truist | Maintains | Buy → Buy | — | $75.25 | $75.06 | -0.3% | +4.3% | +1.9% | +3.5% | +4.5% | +0.9% |
| Oct 28 | BTIG | Maintains | Buy → Buy | — | $75.25 | $75.06 | -0.3% | +4.3% | +1.9% | +3.5% | +4.5% | +0.9% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $75.73 | $75.60 | -0.2% | +2.3% | +1.3% | -1.0% | -2.9% | -2.3% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.47 | $65.28 | -0.3% | -0.3% | +2.4% | +32.9% | +20.9% | +17.5% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.59 | $60.05 | +2.5% | +1.1% | +6.1% | +6.2% | +10.1% | +11.0% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $53.87 | $54.12 | +0.5% | -5.4% | -5.2% | -0.2% | +1.2% | +5.3% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.15 | $49.91 | -0.5% | +1.8% | +2.8% | +7.3% | +8.4% | +11.0% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.49 | $44.45 | -0.1% | +2.4% | +4.8% | +3.0% | +3.2% | +2.6% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.57 | $41.44 | -2.7% | -3.9% | +0.1% | +5.8% | +10.3% | +7.6% |
| Mar 28 | Wedbush | Maintains | Outperform → Outperform | — | $49.44 | $49.47 | +0.1% | -1.1% | -2.2% | -5.2% | -2.5% | -5.9% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $55.95 | $55.90 | -0.1% | +6.8% | +3.0% | -1.9% | -2.1% | -5.3% |
| Mar 11 | BMO Capital | Maintains | Outperform → Outperform | — | $55.95 | $55.90 | -0.1% | +6.8% | +3.0% | -1.9% | -2.1% | -5.3% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.95 | $55.90 | -0.1% | +6.8% | +3.0% | -1.9% | -2.1% | -5.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.35 | $50.08 | +30.6% | +45.9% | +55.8% | +50.3% | +43.2% | +42.8% |
| Mar 10 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $38.35 | $50.08 | +30.6% | +45.9% | +55.8% | +50.3% | +43.2% | +42.8% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $38.50 | $38.24 | -0.7% | +0.4% | -0.1% | +1.4% | -0.4% | +45.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.59 | $40.81 | +8.6% | +2.4% | +2.8% | +2.3% | +3.9% | +2.0% |
| Feb 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.75 | $38.75 | +0.0% | -7.1% | -9.4% | -6.7% | -6.2% | -3.0% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.75 | $38.75 | +0.0% | -7.1% | -9.4% | -6.7% | -6.2% | -3.0% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $37.75 | $37.81 | +0.2% | +3.0% | +0.6% | -2.0% | -0.9% | +2.5% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.75 | $37.81 | +0.2% | +3.0% | +0.6% | -2.0% | -0.9% | +2.5% |
| Feb 4 | JP Morgan | Maintains | Overweight → Overweight | — | $37.20 | $37.55 | +0.9% | +1.0% | +3.5% | +1.5% | +4.5% | +2.1% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.50 | $40.70 | +0.5% | +2.7% | +1.2% | -0.3% | +1.4% | +2.4% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.65 | $43.30 | +4.0% | +11.5% | +9.3% | +7.6% | +7.9% | +5.2% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.39 | $38.27 | -5.2% | -4.3% | +0.6% | +3.1% | +15.0% | +12.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.23 | $46.90 | +1.4% | +0.6% | -6.6% | -7.7% | -11.2% | -11.1% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.79 | $45.25 | +1.0% | +1.9% | +5.0% | +3.1% | +0.3% | -0.0% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $36.21 | $36.63 | +1.2% | -1.2% | +2.7% | +6.9% | +12.1% | +11.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.21 | $36.63 | +1.2% | -1.2% | +2.7% | +6.9% | +12.1% | +11.3% |
| Jul 25 | JP Morgan | Maintains | Overweight → Overweight | — | $41.89 | $41.62 | -0.6% | -0.8% | -3.8% | -7.4% | -10.1% | -10.6% |
No insider trades available.
Data updated apr 26, 2026 9:08pm
· Source: massive.com